Bunkerhill MAC vs Imbio PHA (4.0.0)
AI Verdict
Choose Bunkerhill MAC if…
Choose Bunkerhill MAC if your primary goal is to proactively identify patients at increased long-term cardiovascular risk by detecting and quantifying mitral annular calcification (MAC) on routine, non-gated chest CT scans. This tool is ideal for integrating MAC findings into broader care coordination workflows and leveraging generative AI for clinical reasoning and action within the Carebricks platform.
View Bunkerhill MAC →Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA if you need rapid, automated assessment of cardiac structures from CT pulmonary angiogram (CTPA) scans to aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. This tool is particularly well-suited for situations requiring quick measurements of ventricular and vascular diameters, such as RV/LV ratios, to assess right ventricular dilation in acute or suspected cases.
View Imbio PHA (4.0.0) →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Bunkerhill MAC | Imbio PHA (4.0.0) |
|---|---|---|
| Pricing | Contact for pricing | Unknown |
| Deployment | Cloud-based, integrated with existing EHRs and clinical systems via Carebricks platform. | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). |
| FDA Status | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Bunkerhill MACBunkerhill MAC, through its Carebricks platform, offers advanced features like 'generative AI for clinical reasoning and action' and 'conversational access to the entire patient record' via Carebricks Chat. This suggests a highly interactive and intuitive user experience that extends beyond basic image analysis and integrates deeply into clinical workflows.
Clinical Value
TieBoth tools are FDA-cleared and address significant clinical needs within their respective specialties. Bunkerhill MAC aids in early cardiovascular risk identification and care coordination for MAC, while Imbio PHA assists in the diagnosis and risk stratification of pulmonary embolism and hypertension. Both have demonstrated clinical utility and are deployed in prominent healthcare settings.
Pricing & Value
TieBoth Bunkerhill MAC and Imbio PHA require direct contact for pricing information, indicating a lack of public transparency regarding their cost structures. Without specific pricing details or publicly available return on investment (ROI) studies for either tool, it is not possible to definitively compare their value propositions.
Enterprise Readiness
Imbio PHA (4.0.0)Imbio PHA demonstrates stronger enterprise readiness by explicitly offering both cloud and on-premise deployment options, and by stating it is 'third-party certified by Compliancy Group' for HIPAA compliance. While Bunkerhill MAC is deployed in major health systems, its BAA and HIPAA compliance are only 'likely' stated in the provided facts, and its deployment is primarily cloud-based.
Innovation
Bunkerhill MACBunkerhill MAC stands out with its explicit mention and integration of 'Generative AI for clinical reasoning and action' through the Carebricks platform, which leverages large language models to automate complex workflows and offer conversational access to patient records. This represents a more advanced and transformative application of AI compared to Imbio PHA's focus on automated measurements.
Support & Docs
Imbio PHA (4.0.0)Imbio PHA clearly outlines various support channels, including an online case submission form, phone support (U.S. and India numbers), and email support, and explicitly states that user manuals and other product documentation are available upon request. The provided information for Bunkerhill MAC does not detail its support structure or documentation availability.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Bunkerhill MAC | Imbio PHA (4.0.0) |
|---|---|---|
| Primary Clinical Focus | Detects and quantifies mitral annular calcification (MAC) on routine CT scans, aiding early cardiovascular risk identification. | Automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. |
| Input Scan Type | Routine, non-gated chest CT scans. | CT pulmonary angiogram (CTPA) scans. |
| Key Output/Functionality | AI-powered detection and quantification of Mitral Annular Calcification (MAC); identifies patients at increased cardiovascular risk; supports automated workflows for follow-up and care coordination. | Automated measurement of right and left ventricle diameters, main pulmonary artery and aorta diameters, and RV/LV and PA/Ao ratios; generates annotated DICOM images; provides summary reports in PDF format. |
| Integration | Seamless integration with existing EHRs and clinical systems via Carebricks platform. | Integrates with native DICOM tools and workflows. |
| Specialties | Cardiology, Radiology | Cardiology, Pulmonology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring Bunkerhill MAC and Imbio PHA (4.0.0).